Skip to content
type1.science

Medtronic MiniMed 780G (SmartGuard)

Medtronic

An advanced hybrid closed-loop system whose SmartGuard algorithm delivers automatic correction boluses as often as every 5 minutes and offers an aggressive, adjustable 100 mg/dL (5.6 mmol/L) target. Tubed, paired with Medtronic's own Guardian 4 (or newer Simplera Sync) sensor, with strong trial and real-world time-in-range and the ability to absorb missed or under-estimated meal boluses.

Available nowStrong evidencehybrid-closed-looptubedphone-controlOfficial site ↗

The scorecard

Time in range80

Real-world cohorts average ~76% TIR (Latin America, n=1025) and the US pivotal trial reached 75% overall (78.8% at the 100 mg/dL target); among the strongest of mainstream AID systems.

Hypo protection80

Predictive low-glucose suspension keeps real-world time-below-range low (~2.7% <70 mg/dL; <1% in large cohorts) even while pushing an aggressive target, with no severe-hypo or DKA events in the ADAPT RCT. When lows do happen, the rebound high afterwards was less severe on the 780G than on Control-IQ in a 190-child comparison (rebounds were just as frequent on both).[3]

Automation level70

Meal-detection auto-corrections fire as often as every 5 minutes to absorb missed or under-estimated boluses. In a small crossover meal study (20 adolescents, 10 already using each system — the devices were compared between groups, not randomized within person), the 780G's algorithm was the more reactive of the two after an *unannounced* breakfast — lower 2-hour glucose rise, lower peak, less time above range, more time in range — and also after an announced mixed (carb-plus-protein) meal; the two were equivalent only for an announced pure-carbohydrate meal. It is still a hybrid loop, and announcing your meals still beats not announcing them.[1]

Average glucose80

The 100 mg/dL target and frequent auto-corrections drive low mean glucose: real-world GMI ~6.7-6.95% and trial HbA1c falling to ~7.3% from a high-8% baseline.

Low variability72

Good coefficient-of-variation control in real-world data; large unannounced meals and rapidly absorbing carbs still produce excursions the loop cannot fully blunt.

Exercise handling64

A manually set Temp Target of 150 mg/dL (8.3 mmol/L) raises the target to limit activity lows, but there is no automatic exercise detection.

Customizability70

Adjustable SmartGuard target (100/110/120 mg/dL) and active-insulin time let users tune aggressiveness. Active insulin time is the higher-leverage of the two: across 287 real-world users a 2-hour setting produced more automatic correction boluses and better time-in-range, while the choice of glucose target across the 100-120 mg/dL (5.6-6.7 mmol/L) range made no significant difference.[2]

Access & cost62

FDA-approved (ages 7+) and broadly available across the US, UK, EU, Canada and Australia through durable-medical-equipment channels, though it is a closed, Medtronic-only ecosystem.

Freedom (form factor)46

A tubed pump with a separate body, tubing and an infusion set to carry and disconnect for showering or sport.

Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.

The full picture

The MiniMed 780G is Medtronic's advanced hybrid closed-loop (AHCL) system. It combines a tubed insulin pump, one of Medtronic's own continuous glucose monitors (the Guardian 4 sensor, and in newer markets the disposable Simplera Sync), and the SmartGuard algorithm, which automatically adjusts background insulin and adds correction doses to keep glucose near a target you choose.12

What makes it distinctive is how assertive the algorithm is. You pick a target of 100, 110, or 120 mg/dL (5.6, 6.1, or 6.7 mmol/L); the default and lowest, 100 mg/dL, is the most aggressive of any approved automated pump.31 On top of automated basal, SmartGuard delivers automatic correction boluses as often as every 5 minutes when basal is maxed out and sensor glucose climbs above 120 mg/dL, and its meal-detection feature gives larger corrections when it sees the rapid rise of a missed or under-estimated meal bolus.31

Trial outcomes are strong. In the ADAPT randomized trial, adults with poorly controlled type 1 diabetes (starting HbA1c ~9%) who switched from injections-plus-scanning to the 780G dropped HbA1c by 1.54% to 7.32%, versus almost no change on injections — a 1.42% advantage, with no severe hypoglycemia or ketoacidosis.4 Those gains held at 12 months, and late switchers reproduced them.5 Medtronic's US pivotal trial reported 75% time-in-range overall, 82% overnight, and 78.8% when using the 100 mg/dL target.1 Large real-world datasets agree: across ~1,000 Latin American users, mean GMI was 6.7%, time-in-range 76.5%, and time-below-range just 2.7%, improving with each system generation.6

Automation and meals. This is still a hybrid loop — you announce meals by counting carbs and bolusing. The payoff of the aggressive auto-corrections is that the cost of a forgotten or under-counted meal is smaller than on gentler systems. In a 2025 real-world study of youth and young adults switching to the recommended settings (100 mg/dL target plus 2-hour active-insulin time), time-in-range improved from 71.9% before the switch to 75.0% at 3 months without a significant increase in time below range.7

How it compares on a missed meal. In July 2026 the small CRUMB study gave the site its first direct comparison of the two dominant algorithm designs: 20 adolescents (aged 11-18) — 10 already using the 780G's SmartGuard (a PID controller), 10 already using the Tandem t:slim X2 with Control-IQ (a model-predictive controller) — each ate a test breakfast announced and, after a washout, unannounced, in randomized order. The randomization was of the meal, not of the device: the two algorithms are compared between two groups of ten, not within the same person. When the breakfast was not announced, the 780G came out ahead — a lower 2-hour glucose rise, a lower peak, less time above range and more time in range. It also came out ahead after an announced mixed meal (carbohydrate plus protein). The two systems were equivalent only for an announced pure-carbohydrate meal.8 Read this carefully: ten users per device, no within-person device comparison, and an adolescent pilot design — it is not a verdict on which pump is better overall, and it does not make the 780G a fully closed loop, since announcing your meals still beat not announcing them on both systems. It is a hint, not a finding, that the 780G's more assertive controller is the better safety net when a meal slips through unannounced.

Which setting actually matters. A 2026 analysis of 287 real-world 780G users separated the two things you can tune. A shorter active insulin time (2 hours) was the lever that mattered: it produced more automatic correction boluses and better time-in-range. The glucose target, across its 100-120 mg/dL (5.6-6.7 mmol/L) range, made no significant difference to either.9 Separately, in 190 children and adolescents, rebound highs after a hypo were about as frequent on the 780G as on Control-IQ, but less severe on the 780G.10

Exercise is handled with a manually set Temp Target of 150 mg/dL (8.3 mmol/L) that you turn on before activity to reduce lows; there is no automatic activity detection.3

Ages, indications, and access. The FDA approved the 780G in April 2023 for people aged 7 and older with type 1 diabetes, paired with the Guardian 4 sensor (no fingersticks needed in SmartGuard).111 It is widely available in the US, UK, EU, Canada and Australia. Real-world studies show benefit well beyond the label, including young children aged 2-6 (≈73% TIR),12 youth over a full year,13 all ages in real-world clinics,2 and — though not formally approved for it — pregnancy, where a randomized trial found improved overnight time-in-range and less hypoglycemia.14

What's coming. Medtronic has broadened sensor options: the disposable, all-in-one Simplera Sync sensor gained FDA approval for use with the 780G in April 2025, replacing the bulkier Guardian 4 with a smaller two-step insertion and no overtape.15 The closed, single-vendor ecosystem remains the main trade-off against the more open and DIY platforms.

References

  1. Medtronic. FDA Approves Medtronic MiniMed 780G System — World's First Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections. Medtronic News (2023). https://news.medtronic.com/2023-04-21-FDA-Approves-Medtronic-MiniMed-TM-780G-System-Worlds-First-Insulin-Pump-with-Meal-Detection-Technology-Featuring-5-Minute-Auto-Corrections ↩ ↩2 ↩3 ↩4 ↩5

  2. Elbarbary NS, Ismail EAR. MiniMed 780G advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: real-world users. Diabetol Metab Syndr (2023). https://doi.org/10.1186/s13098-023-01184-w ↩ ↩2

  3. Medtronic / MiniMed. SmartGuard Technology — MiniMed 780G System Support. minimed.com (accessed 2026). https://www.minimed.com/en-us/support/product-support/780g/smartguard-technology/ ↩ ↩2 ↩3

  4. Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol (2022). https://doi.org/10.1016/S2213-8587%2822%2900212-1 ↩

  5. Edd SN, Castañeda J, Choudhary P, et al. Twelve-month results of the ADAPT randomized controlled trial. Diabetes Obes Metab (2023). https://doi.org/10.1111/dom.15217 ↩

  6. Grassi B, Gómez AM, Calliari LE, et al. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America. Diabetes Obes Metab (2023). https://doi.org/10.1111/dom.15023 ↩

  7. Bassi M, Spacco G, Pezzotta F, et al. Real-world efficacy of MiniMed 780G recommended settings (glycemic target 100 mg/dL, active insulin time 2 hours) in youth and young adults with type 1 diabetes. Front Endocrinol (2025). PMID 41019322. https://doi.org/10.3389/fendo.2025.1670266 ↩

  8. Lo Presti D, et al. The CRUMB study: closed-loop response to unannounced mixed and carbohydrates-rich breakfasts. A randomized controlled crossover pilot-study in adolescents with type 1 diabetes (n=20; NCT07455643). Endocrine (2026). https://doi.org/10.1007/s12020-026-04705-5 ↩

  9. Papa G, et al. Effect of Active Insulin Time and Glycemic Targets on Automatic Correction Bolus Delivery (n=287 MiniMed 780G users). J Diabetes Sci Technol (2026). https://doi.org/10.1177/19322968261465689 ↩

  10. Ranjan AG, et al. Rebound Hyperglycemia in Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery Systems (n=190). Diabetes Technol Ther (2026). https://doi.org/10.1177/15209156261467116 ↩

  11. U.S. FDA. PMA Supplement P160017/S091 — Medtronic MiniMed 780G System approval order/summary. accessdata.fda.gov (2023). https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160017S091A.pdf ↩

  12. Abraham MB, Smith GJ, Dart J, et al. Clinical Outcomes with MiniMed 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes. Diabetes Technol Ther (2024). https://doi.org/10.1089/dia.2023.0508 ↩

  13. Passanisi S, Salzano G, Bombaci B, et al. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in Children and Adolescents: A 1-Year Real-World Study. Diabetes Care (2024). https://doi.org/10.2337/dc23-2311 ↩

  14. Benhalima K, Beunen K, Van Wilder N, et al. Advanced hybrid closed loop therapy versus standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a randomised controlled trial. Lancet Diabetes Endocrinol (2024). https://doi.org/10.1016/S2213-8587%2824%2900089-5 ↩

  15. Medtronic. New Simplera Sync sensor for the MiniMed 780G System now FDA approved. Journal of Healthcare Contracting (2025). https://www.jhconline.com/new-simplera-sync-sensor-for-the-minimed-780g-system-now-fda-approved.html ↩

What's next for this

  • →Disposable all-in-one Simplera Sync sensor gained FDA approval for use with the 780G, replacing the bulkier Guardian 4 · April 2025

Sources

  1. [1]Lo Presti D, et al. The CRUMB study: closed-loop response to unannounced mixed and carbohydrates-rich breakfasts. A randomized controlled crossover pilot-study in adolescents with type 1 diabetes (n=20, ages 11-18; NCT07455643 — meal order randomized within person; device, MiniMed 780G vs Tandem t:slim X2 Control-IQ, compared between groups of 10) · peer-reviewed · 2026-07-10
  2. [2]Papa G, et al. Effect of Active Insulin Time and Glycemic Targets on Automatic Correction Bolus Delivery in MiniMed 780G users (n=287) · peer-reviewed · 2026-07-13
  3. [3]Ranjan AG, et al. Rebound Hyperglycemia in Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery Systems (n=190) · peer-reviewed · 2026-07-10